Johnson & Johnson (NYSE:JNJ) on Wednesday reported second-quarter 2026 results that topped Wall Street estimates and raised its full-year sales and adjusted earnings guidance as strength in its Innovative Medicine and MedTech businesses offset continued pressure from several legacy products.
Adjusted earnings rose 4.7% year over year to $2.90 per share, beating the analyst consensus estimate of $2.85.
Sales increased 6.6% to $25.31 billion, ahead of the consensus estimate of $25.047 billion.
Operational sales growth was 5.6%, while adjusted operational growth was 5.7%.
Innovative Medicine Driven By Oncology Innovative Medicine sales rose 7.8%, or 6.8% on an operational basis, to $16.38 billion.
